Breast Cancer

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer

By

The role and impact of religiousness/spirituality in determining physical well-being among survivors of breast cancer is not well understood.

Copy Number Abnormalities May Inform Survival, Drug Resistance

Copy Number Abnormalities May Inform Survival, Drug Resistance

By

For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

High-Risk Breast Cancer Patients May Not Be Adherent to Heart Failure Monitoring

By

There is a paucity of data regarding the cardiotoxicity and the monitoring adherence habits of patients undergoing treatment with trastuzumab or anthracyclines, commonly used therapies among patients with HER2-positive breast cancer.

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

By

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

Breast Cancer (Invasive) Treatment Regimens

The latest breast cancer treatment regimens with detailed drug information such as pertuzamab with trastuzumab and docetaxel.

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer

By

The FDA based its approval on the results of a triplet of phase 3 studies, the MONALEESA-2, MONALEESA-3, and MONALEESA-7.

Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

By

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

Aggressive Follow-Up Imaging in Breast Cancer Is Geography-Specific

By

Variations in the use and frequency of advanced imaging post-surgery in patients with breast cancer were observed across regions of the United States.

FDA-Approved Breast Cancer Drug Treatments

Treatment chart with usual dosage, strength, and formulation of FDA approved medications for breast cancer.

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

Adding Ovarian Suppression May Improve Survival Outcomes in Premenopausal Breast Cancer

By

Updated results of the SOFT and TEXT trial suggest that adding ovarian suppression to exemestane or tamoxifen could improve survival outcomes.

Tucatinib May Be A Safe, Novel Treatment for <i>ERBB2/HER2</i>-Positive Breast Cancer

Tucatinib May Be A Safe, Novel Treatment for ERBB2/HER2-Positive Breast Cancer

By

For this phase 1b study, researchers enrolled 57 patients with ERBB2/HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

By

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

Trastuzumab Retreatment May Be Safe and Effective in Breast Cancer Recurrence

By

The effectiveness of trastuzumab in retreating patients with recurrence who received it during perioperative therapy is the focus of a new study.

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

Do the Risks of Direct-to-Consumer Testing Outweigh the Benefits?

By

There are benefits and drawbacks to the public availability to DTC mutation tests.

<i>ARID1A</i> Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

By

New findings bolster the case for the predictive utility of ARID1A mutations.

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

By

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

By

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

By

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer

Six-Month Trastuzumab Sufficient for HER2-Positive Early Stage Breast Cancer

By

Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

Endocrine Therapy Alone Is Not Inferior to Chemoendocrine Therapy in Breast Cancer With Oncotype DX Scores Between 11 and 26

By

The effect of combination chemotherapy and endocrine therapy has not been fully clarified among patients with Oncotype DX recurrence scores 11-25.

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

MONALEESA 3: Ribociclib Provides Significant PFS in Postmenopausal Women With ER+/HER- Advanced Breast Cancer Regardless of Prior Endocrine Therapy

By

With a greater than 40% decreased risk for disease progression, the combination of ribociclib and fulvestrant was significantly better than that of placebo and fulvestrant for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer.

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

PALOMA 3: Elucidating Resistance Mechanisms to Palbociclib and Fulvestrant

By

It is important to understand mechanisms of resistance with these inhibitors to determine future treatment strategies.

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

SANDPIPER: First Trial to Show Modest Benefit of Taselisib in Postmenopausal Women With ER+/HER- Advanced Breast Cancer

By

Despite modest improvements in progression-free survival, patients experienced considerable side effects with the addition of taselisib.

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

First-in-Class ICOS Agonist Alone or In Combination May Be Effective For Advanced Cancer

By

Researchers assigned patients with various types of relapsed/refractory cancer to receive escalating doses of JTX-2011 alone or plus nivolumab.

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

Pertuzumab, Trastuzumab, Capecitabine May Prolong Overall Survival in HER2-Positive Breast Cancer

By

Although progression-free survival was not significantly increased, long-term overall survival may be improved with pertuzumab.

Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

By

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

Computer analysis is not better than human clinical evaluation when it comes to measuring breast density

In the United States, the standard for monitoring breast density is through the Breast Imaging Reporting and Data System (BI-RADS). There has been recent concern regarding the reproducibility of this system, as there is subjectivity in the breast density estimated by radiologists.

Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

By

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

Mentally, Physically Demanding Jobs May Predict Unemployment After Breast Cancer Surgery

By

Understanding various factors associated with unemployment may help to guide breast cancer management to increase the rate of returning to work.

Circulating Tumor Cells Predictive of Adjuvant Radiotherapy Benefit in Early Breast Cancer

Circulating Tumor Cells Predictive of Adjuvant Radiotherapy Benefit in Early Breast Cancer

By

Researchers determined that there was a significant association between overall survival and adjuvant RT when factoring in CTC status.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs